ClinicalTrials.gov
public full text
Public Domain
A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors
This is an open-label, multi-center, dose-escalation clinical study to evaluate the safety, feasibility, and preliminary efficacy of IMC002 in patients with CLDN18.2 positive digestive system tumors including but not limited to advanced gastric cancer, esophagogastric junction adenocarcinoma, and advanced pancreatic cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial#896916
- BGT007H Cells for the Treatment of Recurrent/Refractory Gastrointestinal Tumors#887069
- IMaC - Immune Pathways in Oesophagogastric Cancer#911249
- A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy#1161535
- Bispecific antibodies in gastrointestinal cancers: current applications and future perspectives.#1080696
Record · ID 1138727
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive